Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | FBP1 | P09467 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051059 | 0.85 | CA1 (0.55) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL822302 | 0.83 | KMT2A (0.59) | KMT2AACHESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL29468572 | 0.83 | KMT2A (0.59) | KMT2AACHESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL16566280 | 0.82 | HTT (0.61) | ACHEALDH1A1 | |
| SCHEMBL17737834 | 0.82 | KMT2A (0.46) | KMT2AIDO1SMN1; SMN2ALDH1A1FBP1 | |
| SCHEMBL12810488 | 0.82 | KMT2A (0.53) | KMT2AIDO1ACHESMN1; SMN2MEN1 | |
| SCHEMBL1706770 | 0.82 | KMT2A (0.53) | KMT2AIDO1ACHESMN1; SMN2MEN1 | |
| SCHEMBL8264434 | 0.82 | KMT2A (0.53) | KMT2AIDO1ACHESMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL11279258 | 0.81 | KMT2A (0.57) | KMT2AACHESMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL330676 | 0.81 | KMT2A (0.57) | KMT2AACHESMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4146652-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | Merck Patent GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-115515959-A | Tricyclic heterocycles as TEAD binders | 默克专利股份公司 | 2022-12-23 | — | — | CN | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-20040142950-A1 | Amide and ester matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-07-22 | — | — | US | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024073624-A2 | ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-0470103-B1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS | HOECHST AG (DE) | 1994-07-27 | — | — | EP | disclosed |
| EP-0470103-A1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS. | HOECHST AG (DE) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990013537-A1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-11-15 | — | — | WO | disclosed |
| CN-86108499-A | 1 of novel fluorine, 4-dihydropyridine compounds and their preparation method and as the purposes of medicine | — | 1987-07-15 | — | — | CN | disclosed |
| EP-0093484-A2 | Antibacterial monic acid derivatives | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | KMT2A 2683/4885IDO1 3982/4885ACHE 4878/4885 |
| US-20040142950-A1 | Amide and ester matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | KMT2A 930/4885IDO1 1219/4885ACHE 1635/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | KMT2A 2680/4885IDO1 3847/4885ACHE 4874/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | KMT2A 3227/4885IDO1 3670/4885ACHE 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.